These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20812278)

  • 1. Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells.
    Freudlsperger C; Dahl A; Hoffmann J; Reinert S; Schumacher U
    Phytother Res; 2010 Sep; 24(9):1354-8. PubMed ID: 20812278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
    Freudlsperger C; Thies A; Pfüller U; Schumacher U
    Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
    Felenda JE; Turek C; Stintzing FC
    J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro.
    Thies A; Nugel D; Pfüller U; Moll I; Schumacher U
    Toxicology; 2005 Feb; 207(1):105-16. PubMed ID: 15590126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
    Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
    Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
    Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H
    Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
    Smith AG; Beaumont KA; Smit DJ; Thurber AE; Cook AL; Boyle GM; Parsons PG; Sturm RA; Muscat GE
    Int J Biochem Cell Biol; 2009 Apr; 41(4):844-52. PubMed ID: 18822385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
    Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
    Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
    Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
    Yee LD; Williams N; Wen P; Young DC; Lester J; Johnson MV; Farrar WB; Walker MJ; Povoski SP; Suster S; Eng C
    Clin Cancer Res; 2007 Jan; 13(1):246-52. PubMed ID: 17200362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
    Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
    Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro.
    Valentiner U; Carlsson M; Erttmann R; Hildebrandt H; Schumacher U
    Toxicology; 2005 Sep; 213(1-2):157-68. PubMed ID: 16009482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro.
    Freudlsperger C; Moll I; Schumacher U; Thies A
    Anticancer Drugs; 2006 Mar; 17(3):325-32. PubMed ID: 16520661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines.
    Urech K; Buessing A; Thalmann G; Schaefermeyer H; Heusser P
    Anticancer Res; 2006; 26(4B):3049-55. PubMed ID: 16886633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
    Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
    Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.